Akebia Therapeutics (AKBA) Amortization - Intangibles (2019 - 2024)
Akebia Therapeutics (AKBA) posted quarterly Amortization - Intangibles of $9.0 million for Q4 2024, little changed year-over-year from $9.0 million in Q1 2024, and little changed quarter-over-quarter from $9.0 million in Q3 2024.
Akebia Therapeutics (AKBA) Amortization - Intangibles (2019 - 2024) Analysis & Trends
Akebia Therapeutics (AKBA) has reported Amortization - Intangibles for 6 consecutive years, with $9.0 million the latest figure, recorded in Q4 2024.
- In Q4 2024, Amortization - Intangibles changed 0.0% year-over-year to $9.0 million; the TTM figure through Sep 2025 stood at $9.0 million (down 75.0% YoY), while the FY2024 annual figure was $36.0 million, changed 0.0% from the prior year.
- Amortization - Intangibles was little changed at $9.0 million in Q4 2024 per AKBA's latest filing, from $9.0 million in the prior quarter.
- Across five years, Amortization - Intangibles topped out at $9.1 million in Q2 2020 and bottomed at $6.1 million in Q3 2020.
- Historically, Amortization - Intangibles has averaged $8.8 million across 5 years, with a median of $9.0 million in 2021.
- Annual changes were most pronounced in 2020 — Amortization - Intangibles plunged 32.91% — and 2021, when it jumped 47.58%.
- Akebia Therapeutics' Amortization - Intangibles stood at $8.3 million in 2020, then advanced by 8.42% to $9.0 million in 2021, then changed by 0.0% to $9.0 million in 2022, then changed by 0.0% to $9.0 million in 2023, then changed by 0.0% to $9.0 million in 2024.
- Business Quant data shows AKBA's Amortization - Intangibles at $9.0 million in Q4 2024, $9.0 million in Q3 2024, and $9.0 million in Q2 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Akebia Therapeutics | 249.25 Mn | 93.70 Mn | 38.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 9.01 Mn |
| Sep 30, 2024 | 9.01 Mn |
| Jun 30, 2024 | 9.01 Mn |
| Mar 31, 2024 | 9.01 Mn |
| Dec 31, 2023 | 9.01 Mn |
| Sep 30, 2023 | 9.01 Mn |
| Jun 30, 2023 | 9.01 Mn |
| Mar 31, 2023 | 9.01 Mn |
| Dec 31, 2022 | 9.01 Mn |
| Sep 30, 2022 | 9.01 Mn |
| Jun 30, 2022 | 9.01 Mn |
| Mar 31, 2022 | 9.01 Mn |
| Dec 31, 2021 | 9.01 Mn |
| Sep 30, 2021 | 9.01 Mn |
| Jun 30, 2021 | 9.01 Mn |
| Mar 31, 2021 | 9.01 Mn |
| Dec 31, 2020 | 8.31 Mn |
| Sep 30, 2020 | 6.11 Mn |
| Jun 30, 2020 | 9.10 Mn |
| Mar 31, 2020 | 9.10 Mn |